Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders

Stam, Cornelis J.

doi:10.1016/j.jns.2009.08.028

Cited by 237 publications

(208 citation statements)

References 63 publications

Supporting

Mentioning

185

Contrasting

Unclassified

Order By: Relevance

“…The full potential of neurodynamic time-sensitive biomarkers using electroencephalography (EEG) [289] and magnetoencephalography (MEG) [290] for quantification of degenerative brain changes during various stages of AD has yet to be realized. Subtle but consistent deviations in the electromagnetic neuronal dynamics have been shown to precede explicit cognitive manifestations in AD [291] which could enable a future role of EEG/MEG biomarkers not only as a clinical diagnosis and treatment option, but also as a new mode for AD stage discovery.…”

Section: Neuroelectrical and Neuromagnetic Markersmentioning

confidence: 99%

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel

Lista

Teipel

et al. 2014

Biochemical Pharmacology

105

View full text Add to dashboard Cite

Recent advances in understanding the molecular mechanisms underlying various paths toward the pathogenesis of Alzheimer's disease (AD) has begun to provide new insight for interventions to modify disease progression. The evolving knowledge gained from multidisciplinary basic research has begun to identify new concepts for treatments and distinct classes of therapeutic targets; as well as putative disease-modifying compounds that are now being tested in clinical trials. There is a mounting consensus that such disease modifying compounds and/or interventions are more likely to be effectively administered as early as possible in the cascade of pathogenic processes preceding and underlying the clinical expression of AD. The budding sentiment is that "treatments" need to be applied before various molecular mechanisms converge into an irreversible pathway leading to morphological, metabolic and functional alterations that characterize the pathophysiology of AD. In light of this, biological indicators of pathophysiological mechanisms are desired to chart and detect AD throughout the asymptomatic early molecular stages into the prodromal and early dementia phase. A major conceptual development in the clinical AD research field was the recent proposal of new diagnostic criteria, which specifically incorporate the use of biomarkers as defining criteria for preclinical stages of AD. This paradigm shift in AD definition, conceptualization, operationalization, detection and diagnosis represents novel fundamental opportunities for the modification of interventional trial designs. This perspective summarizes not only present knowledge regarding biological markers but also unresolved questions on the status of surrogate indicators for detection of the disease in asymptomatic people and diagnosis of AD

show abstract

Section: Neuroelectrical and Neuromagnetic Markersmentioning

confidence: 99%

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel

Lista

Teipel

et al. 2014

Biochemical Pharmacology

105

View full text Add to dashboard Cite

show abstract

“…97,98 Because the net current of pyramidal neuron depolarization is oriented toward the cortical surface, MEG is most sensitive for detecting signals arising from sulcal walls, which are directed perpendicular to the skull. 98,99 MEG has intrinsically high temporal resolution, limited only by the sampling frequency of the electronics, 100 which is an advantage over other functional neuroimaging methods, such as fMRI. However, MEG has inferior spatial resolution, largely because a single cortical source of signal can be detected by multiple adjacent scalp sensors.…”

Section: Magnetoencephalographymentioning

confidence: 99%

Imaging Evidence and Recommendations for Traumatic Brain Injury: Advanced Neuro- and Neurovascular Imaging Techniques

Wintermark

Sanelli

Anzai

et al. 2014

AJNR Am J Neuroradiol

112

View full text Add to dashboard Cite

SUMMARY:Neuroimaging plays a critical role in the evaluation of patients with traumatic brain injury, with NCCT as the first-line of imaging for patients with traumatic brain injury and MR imaging being recommended in specific settings. Advanced neuroimaging techniques, including MR imaging DTI, blood oxygen level-dependent fMRI, MR spectroscopy, perfusion imaging, PET/SPECT, and magnetoencephalography, are of particular interest in identifying further injury in patients with traumatic brain injury when conventional NCCT and MR imaging findings are normal, as well as for prognostication in patients with persistent symptoms. These advanced neuroimaging techniques are currently under investigation in an attempt to optimize them and substantiate their clinical relevance in individual patients. However, the data currently available confine their use to the research arena for group comparisons, and there remains insufficient evidence at the time of this writing to conclude that these advanced techniques can be used for routine clinical use at the individual patient level. TBI imaging is a rapidly evolving field, and a number of the recommendations presented will be updated in the future to reflect the advances in medical knowledge. ABBREVIATIONS:BOLD ϭ blood oxygen level-dependent; FA ϭ fractional anisotropy; MD ϭ mean diffusivity; MEG ϭ magnetoencephalography; TBI ϭ traumatic

show abstract

“…Compared with fMRI which gives an indirect estimate of brain activity through hemodynamic responses, MEG provides a direct measure of electrophysiological activity, reflecting neuronal communication with great temporal resolution (Hämäläinen et al 1993) and, therefore, allowing the investigation of several brain rhythms (1-100 Hz). Indeed, MEG oscillatory activity has been proven useful in measuring both spontaneous and task-induced brain rhythms in normal and pathological aging (Fernández et al 2006;Osipova et al 2006;Stam 2010;Leirer et al 2011;Bajo et al 2010;Zamrini et al 2011).…”

Section: Introductionmentioning

confidence: 99%

Synchronization during an internally directed cognitive state in healthy aging and mild cognitive impairment: a MEG study

López

Garcés

Cuesta

et al. 2014

AGE

View full text Add to dashboard Cite

Mild cognitive impairment (MCI) is a stage between healthy aging and dementia. It is known that in this condition the connectivity patterns are altered in the resting state and during cognitive tasks, where an extra effort seems to be necessary to overcome cognitive decline. We aimed to determine the functional connectivity AGE (2014) pattern required to deal with an internally directed cognitive state (IDICS) in healthy aging and MCI. This task differs from the most commonly employed ones in neurophysiology, since inhibition from external stimuli is needed, allowing the study of this control mechanism. To this end, magnetoencephalographic (MEG) signals were acquired from 32 healthy individuals and 38 MCI patients, both in resting state and while performing a subtraction task of two levels of difficulty. Functional connectivity was assessed with phase locking value (PLV) in five frequency bands. Compared to controls, MCIs showed higher PLV values in delta, theta, and gamma bands and an opposite pattern in alpha, beta, and gamma bands in resting state. These changes were associated with poorer neuropsychological performance. During the task, this group exhibited a hypersynchronization in delta, theta, beta, and gamma bands, which was also related to a lower cognitive performance, suggesting an abnormal functioning in this group. Contrary to controls, MCIs presented a lack of synchronization in the alpha band which may denote an inhibition deficit. Additionally, the magnitude of connectivity changes rose with the task difficulty in controls but not in MCIs, in line with the compensation-related utilization of neural circuits hypothesis (CRUNCH) model.

show abstract

Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders

Cited by 237 publications

References 63 publications

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Imaging Evidence and Recommendations for Traumatic Brain Injury: Advanced Neuro- and Neurovascular Imaging Techniques

Synchronization during an internally directed cognitive state in healthy aging and mild cognitive impairment: a MEG study

Contact Info

Product

Resources

About